HER2 Mutation vs Amplification: Different Biomarker Questions
HER2 is commonly used to refer to ERBB2. An ERBB2 sequence mutation, ERBB2 amplification and HER2 protein expression are different measurements that can carry different implications depending on the tumour type and validated assay.
Quick Answer
HER2 is commonly used to refer to ERBB2. An ERBB2 sequence mutation, ERBB2 amplification and HER2 protein expression are different measurements that can carry different implications depending on the tumour type and validated assay.
Three Different Measurements
Sequencing can identify an ERBB2 variant in the gene sequence. Copy-number methods assess amplification, while immunohistochemistry assesses protein expression. These do not measure the same property.
A tumour can have one of these findings without another, and terminology may vary by disease-specific testing guideline. The assay and scoring system must be kept with the result.
Why Disease Context Changes Meaning
HER2 testing has established workflows in some cancer types and different evidence bases in others. A result should be interpreted using the disease-appropriate method rather than transplanted from another tumour type.
The current regulatory label, specimen quality and testing standard matter for any clinical use. This page explains the distinction; it does not determine eligibility or recommend treatment.
Key Takeaways
- ·ERBB2 mutation, amplification and protein expression are distinct biomarker findings.
- ·The test method and tumour type are part of the result.
- ·Do not infer one HER2 measurement from another.
Put these genes in pathway context
Frequently asked questions
What is the key idea in HER2 Mutation vs Amplification: Different Biomarker Questions?
HER2 is commonly used to refer to ERBB2. An ERBB2 sequence mutation, ERBB2 amplification and HER2 protein expression are different measurements that can carry different implications depending on the tumour type and validated assay.
What should be kept with the result or mechanism?
ERBB2 mutation, amplification and protein expression are distinct biomarker findings. The test method and tumour type are part of the result. Do not infer one HER2 measurement from another.
References
Continue Reading
EGFR, HER2, HER3 and HER4: The ERBB Receptor Family
2 min read
EGFR L858R: Understanding the Exon 21 Mutation
3 min read
EGFR Mutations in NSCLC: Testing, Inhibitors and Resistance
5 min read
HER2 Amplification: Mechanism, Targeted Therapy, and Resistance
4 min read
HER2 (ERBB2) Exon 20 Insertions in Lung Cancer
3 min read
How Antibody-Drug Conjugates Work: Targeted Chemotherapy Delivery
4 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
HER2 has 1000+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.